as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025.
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa.
Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...
Causes: Butterfly disease refers to a group of rare, inherited diseases that cause the skin to be very fragile and to blister easily. There are around 30 subtypes of butterfly disease, and these are ...
Scientists are leading research into whether ‘spray on, wash off’ bandages will be a viable alternative to those currently used by those living with Epidermolysis Bullosa.
The re-transcribed DNA is then integrated into the genome of the host cell (Figure 2). This process requires the absence of the nuclear membrane and thus is restricted to the M-phase of ...
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday. A number of other analysts ...
Research into new bandaging aims to ease the agony experienced by those living with genetic skin condition Epidermolysis Bullosa (EB), commonly referred to as 'butterfly skin'.